{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"INTerpath-002","nct_id":"NCT06077760","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=interpath-002-nct06077760. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"INTerpath-002","arms":[{"description":"Participants will receive 1 mg of intismeran autogene via intramuscular (IM) injection once every 3 weeks for 9 doses PLUS 400 mg of pembrolizumab via intravenous (IV) infusion once every 6 weeks for up to 9 doses until disease recurrence or unacceptable toxicity or for a total treatment duration of up to approximately 1 year, whichever is sooner.","label":"Intismeran autogene + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants will receive intismeran autogene-matched placebo via IM injection once every 3 weeks for 9 doses PLUS 400 mg of pembrolizumab via IV infusion once every 6 weeks for up to 9 doses until disease recurrence or unacceptable toxicity or for a total treatment duration of up to approximately 1 year, whichever is sooner.","label":"Placebo + Pembrolizumab","type":"ACTIVE_COMPARATOR"}],"collaborators":["ModernaTX, Inc."],"completion_date":{"date":"2035-12-21","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":868,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Intismeran autogene","otherNames":["mRNA-4157","V940"],"type":"BIOLOGICAL"},{"name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Placebo","otherNames":[],"type":"OTHER"}],"last_update":"2026-09-18","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-06-25","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease- Free Survival (DFS)","timeFrame":"Up to ~78 months"}],"references":[],"start_date":{"date":"2023-12-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)","url":"https://clinicaltrials.gov/study/NCT06077760"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/interpath-002-nct06077760"}